Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | LAP3 | P28838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10919731 | 0.82 | KDM4E (0.36) | GPR84 | |
| SCHEMBL13134411 | 0.80 | TSHR (0.37) | GPR84 | |
| SCHEMBL3983731 | 0.79 | SLC6A2 (0.37) | HTR2AHTR2CSLC6A4 | |
| SCHEMBL6776516 | 0.77 | HPGD (0.41) | — | |
| Hydrochloric Acid SCHEMBL27469220 | 0.76 | HPGD (0.40) | — | |
| SCHEMBL15780712 | 0.75 | CYP2A6 (0.35) | — | |
| SCHEMBL2961435 | 0.72 | UGT2B7 (0.38) | — | |
| SCHEMBL9742492 | 0.71 | IDO1 (0.39) | HTR2ASLC6A4 | |
| SCHEMBL10859634 | 0.71 | AOC3 (0.40) | HTR2A | |
| SCHEMBL27666074 | 0.69 | GPR84 (0.32) | GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632861-B2 | 1-Isobenzofuranethanamine, 1-[[[3,5-bis(trifluoromethyl)phenyl]methoxy]methyl]-1,3-dihydro-N,N-dimethyl-; use in treating a disorder associated with aberrant levels of tachykinins or serotonin; nerve system disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | claimed |
| WO-2009064684-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-22 | — | — | WO | claimed |
| US-20090124613-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124613-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | CNR1, CNR2, PMP22 | HTR2A 226/4885GPR84 854/4885HTR2C 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.